Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crovalimab for prevention of vaso-occlusive episodes in sickle cell disease
NL-OMON60597Phase 2Completed
- Sponsor
- Roche
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of crovalimab, sponsored by Roche. Started Sep 2023; status: completed.
02
Drugs
crovalimab
Beyond the preview
Go deeper on NL-OMON60597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60597.